Prov-Nova Bio Technologies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-06-2024
- Paid Up Capital ₹ 0.10 M
as on 29-06-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 527.35%
(FY 2022)
- Profit 163.26%
(FY 2022)
- Ebitda 3213.94%
(FY 2022)
- Net Worth 378.16%
(FY 2022)
- Total Assets -25.40%
(FY 2022)
About Prov-Nova Bio Technologies
The Company is engaged in the Environment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Purshottam Bhutra, Dilip Toshniwal, and Durga Jhawar serve as directors at the Company.
- CIN/LLPIN
U20100MH2020PTC348554
- Company No.
348554
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Oct 2020
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Prov-Nova Bio Technologies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Purshottam Bhutra  | Director | 23-Oct-2020 | Current |
| Dilip Toshniwal | Director | 10-Jan-2021 | Current |
| Durga Jhawar | Nominee Director | 23-Oct-2020 | Current |
Financial Performance and Corporate Structure Insights of Prov-Nova Bio Technologies.
Prov-Nova Bio Technologies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 527.35% increase. The company also saw a substantial improvement in profitability, with a 163.26% increase in profit. The company's net worth Soared by an impressive increase of 378.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prov-Nova Bio Technologies?
Unlock access to Prov-Nova Bio Technologies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prov-Nova Bio Technologies?
Prov-Nova Bio Technologies has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prov-Nova Bio Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prov-Nova Bio Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
